Corp 1000

UBS: LIlly’s Type 2 diabetes and obesity treatment could be ‘one of the best-selling drugs in history’

Shares of Eli Lilly & Co. Inc. gained 2.5% in premarket trading on Thursday after UBS upgraded the stock to buy from neutral, saying Mounjaro, the company’s newly approved Type 2 diabetes drug, could be “the biggest drug ever.” UBS analysts predict peak sales of $25 billion if the therapy is also approved as a treatment for weight management in people with obesity. “Tirzepatide’s robust efficacy in both obesity and [Type 2 diabetes] should drive sales into a range that we believe could see this being one of the best-selling drugs in history,” the analysts told investors in a note on Thursday. The Food and Drug Administration in May approved Mounjaro as Type 2 diabetes treatment, and Lilly is expected to file for approval of the same drug as a weight-management therapy after clinical research shared last spring showed that the drug helped people lose up to 22% of their body weight. Lilly’s stock is up 7.3% so far this year, while the broader S&P 500 has declined 20.5%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit for more information on this news.

Previous post Affirm stock heads higher as company notches BNPL deal with Amazon in Canada
Next post Nearly 6 in 10 donors may give more to charity despite economic fears, study finds